Taisho says $5bn management buyout will rev up business
Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi
Protecting the immunocompromised: Preventative measures agai...
COVID-19 vaccines are not as effective in immunocompromised individuals as they are in the general population, due to an inability to produce a robust protective response to the vaccine.
Daiichi Sankyo unit claims $182m in Novartis patent dispute
Novartis has settled a lawsuit brought by Daiichi Sankyo’s Plexxikon subsidiary, paying $180 million to resolve claims that its Tafinlar cancer drug infringed US patents h
Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH
Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuri
A strategic approach to local affiliates in the global era
While global harmonisation remains the holy grail, the reality is that pharmaceutical companies still face significant challenges navigating regulatory differences.
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
3rd mRNA Analytical Development Summit
180+ Technical mRNA Specialists | 35+ Expert Speakers | 2 Content Streams
6th Chronic Kidney Disease Drug Development Summit
The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to strengthen proteinuria and GFR slope as surrogates for long-term outcomes, and a wave of
5th Targeted Radiopharmaceuticals Summit Europe 2023
With the recent double whammy of Bayer and Novartis both strategically investing in Bicycle Therapeutics to develop radioconjugates for oncology targets; mergers, acquisitions and collabora
2nd Medical Device Software Development Europe 2024
As device developers of all sizes grapple with the updated transition timeline for EU MDR compliance and the recent EU AI Act approval falls short of expectations, the question looms: how can regul
8th Tumor Models San Francisco Summit 2024
Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the fie